[
  {
    "question": "pregnancy is risk factor for?",
    "option_a": "RLS",
    "option_b": "Periodic limb movement",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Restless Legs Syndrome (RLS) is a neurological sensorimotor disorder characterized by an irresistible urge to move the legs, often accompanied by unpleasant dysesthesias that are typically worse at rest and in the evening or nighttime. It is a clinical diagnosis based on patient history and symptom description. The underlying mechanisms of RLS involve dysregulation of central dopaminergic pathways and abnormal iron metabolism within the brain. Pregnancy predisposes to RLS due to several factors\u2014hormonal fluctuations, increased circulatory demands leading to relative iron deficiency, and metabolic changes can trigger or worsen symptoms in predisposed individuals. In pregnant women, especially during the third trimester, RLS symptoms are common. Patients report uncomfortable leg sensations with an urge to move that typically worsen during rest and improve with movement, leading to sleep disturbances. Evaluating iron status is paramount as iron deficiency is a modifiable contributor. The diagnosis of RLS is clinical, based on the patient\u2019s history and criteria (urge to move, onset/worsening during rest, relief with movement, and circadian pattern). Differential diagnoses include peripheral neuropathy, nocturnal leg cramps, and akathisia. A detailed history and examination, along with evaluation of iron levels (serum ferritin), help differentiate these conditions. Management begins with non\u2010pharmacologic measures such as improved sleep hygiene, moderate exercise, leg massages, and avoidance of exacerbating substances (e.g., caffeine). Iron supplementation is recommended when deficiency is documented. Pharmacologic therapy in pregnancy is approached with caution; dopaminergic agents may be considered in severe cases only after careful risk\u2013benefit evaluation. Current guidelines stress conservative management in pregnant women. Option A (RLS) is correct because numerous studies have shown that pregnancy increases the risk of developing or exacerbating RLS due to physiological factors like iron deficiency. Option B (Periodic limb movement) describes involuntary limb movements during sleep that often coexist with RLS but are not in themselves directly linked as a risk factor in pregnancy. Options C and D are not provided. 1. RLS is highly prevalent in pregnancy, particularly in the later trimesters. 2. Iron deficiency is a key modifiable risk factor in pregnancy-related RLS. 3. Symptoms often improve or resolve postpartum. Recent research underscores the relationship between iron metabolism and RLS pathogenesis, especially during pregnancy. Updated guidelines recommend routine evaluation of iron status in pregnant patients with RLS symptoms and advocate for non-pharmacologic interventions as first-line therapy, reserving medications for refractory cases after thorough risk\u2013benefit analysis.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Excessive daytime sleep and increasing in eating habits: (Narcolepsy)",
    "option_a": "SSRI",
    "option_b": "Methylphenydate (According to uptodate)",
    "option_c": "Sodium oxybate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS) and may present with other REM sleep phenomena such as cataplexy, hypnagogic hallucinations, and sleep paralysis. The condition leads to fragmented nocturnal sleep and difficulty maintaining wakefulness. Narcolepsy is primarily associated with the loss of orexin (hypocretin)\u2013producing neurons in the lateral hypothalamus, leading to dysregulation of the sleep\u2013wake cycle. Genetic predisposition (such as the HLA DQB1*06:02 allele) and environmental factors contribute to its pathogenesis. Clinically, patients experience unrelenting daytime sleepiness causing difficulty in school, work, and social situations. Although increased eating habits are not a classical hallmark, weight gain and appetite changes can be observed in some patients, potentially related to altered metabolism and reduced physical activity. The diagnostic workup typically involves an overnight polysomnography (PSG) to exclude other sleep disorders, followed by a Multiple Sleep Latency Test (MSLT) to assess sleepiness and REM onset. Differential considerations include idiopathic hypersomnia, obstructive sleep apnea, and mood disorders causing fatigue. First-line treatment for EDS in narcolepsy is generally modafinil or armodafinil. However, in scenarios where modafinil is not available or not tolerated, stimulant medications like methylphenidate (option B) are acceptable alternatives. In pregnant patients, the use of stimulants is generally reserved for severe cases due to potential fetal risks (most stimulants are FDA Pregnancy Category C), and non-pharmacologic measures should be maximized. For lactating mothers, the potential for drug excretion in breast milk necessitates close monitoring and risk assessment. Sodium oxybate is generally reserved for improving nighttime sleep consolidation and reducing cataplexy and is contraindicated or used with extreme caution in pregnancy. Option A (SSRI) is more appropriate for managing cataplexy by suppressing REM sleep rather than for treating EDS. Option B (Methylphenidate) acts as a CNS stimulant improving wakefulness and is an acceptable option when modafinil is not available. Option C (Sodium oxybate) is primarily used for patients with cataplexy and disrupted nocturnal sleep rather than isolated EDS. 1. Narcolepsy is characterized by a loss of orexin-producing neurons, leading to EDS. 2. Although modafinil is the preferred first-line agent for EDS, methylphenidate is a viable alternative. 3. Special populations (pregnant and lactating women) require cautious use of stimulant medications with an emphasis on non-pharmacologic approaches. The latest guidelines and UpToDate recommendations continue to prioritize modafinil for the treatment of EDS in narcolepsy. However, methylphenidate remains an important second-line option when modafinil is contraindicated or unavailable. Recent research emphasizes a holistic management approach that includes lifestyle modifications, scheduled naps, and careful monitoring in special populations such as pregnant and lactating patients.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Excessive daytime sleep and increase in eating habits:",
    "option_a": "SSRI",
    "option_b": "Methylphenedate",
    "option_c": "oxybate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Narcolepsy is a central disorder of hypersomnolence marked by excessive daytime sleepiness (EDS), which may sometimes coincide with metabolic changes, including alterations in eating habits. While EDS is the defining symptom, weight gain or increased appetite can occur due to changes in activity levels and circadian dysregulation. The condition is primarily due to the loss of orexin-producing neurons in the hypothalamus, resulting in a disrupted regulation of sleep and wakefulness. Genetic predispositions, especially with the HLA DQB1*06:02 allele, have been well established in affected individuals. Patients with narcolepsy predominantly present with pronounced daytime sleepiness that can lead to inadvertent sleep episodes. Although increasing eating habits are not the diagnostic hallmark, secondary metabolic changes, including weight gain, may be noted. The presentation should be differentiated from other hypersomnolence disorders. Diagnosis of narcolepsy is made with a combination of overnight polysomnography and a Multiple Sleep Latency Test (MSLT). Differential diagnoses include idiopathic hypersomnia, obstructive sleep apnea, and other sleep-related disorders, which can be differentiated based on clinical history and sleep study findings. While modafinil/armodafinil remains the first-line treatment for managing EDS, methylphenidate (option B) is an acceptable alternative in situations where modafinil is either not available or not well tolerated. In pregnant patients, stimulants are cautiously used (typically Category C) with preference given to non-pharmacologic behavioral strategies. For lactating mothers, the decision should be individualized after a careful assessment of the risks and benefits given the potential for drug transmission via breast milk. Option A (SSRI) is generally used for the treatment of cataplexy rather than for alleviating EDS. Option B (Methylphenidate) serves as a CNS stimulant and is effective in reducing EDS, thus representing an appropriate choice in this scenario. Option C (Oxybate) is usually reserved for managing cataplexy and consolidating sleep at night, not primarily for addressing daytime sleepiness. 1. Narcolepsy is frequently associated with orexin deficiency resulting in overwhelming daytime sleepiness. 2. Modafinil is the gold standard treatment, but methylphenidate remains a valuable alternative. 3. Treatment in special populations, such as pregnant or breastfeeding women, requires a careful risk\u2013benefit assessment. Contemporary clinical guidelines continue to support the use of modafinil as first-line therapy for EDS in narcolepsy, with methylphenidate as a recognized alternative. Recent research also highlights the importance of comprehensive, multidisciplinary management including behavioral modifications and scheduled naps, with particular attention given to the safety profiles of agents in pregnant and lactating patients.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Excessive daytime sleep and increase in eating habits:",
    "option_a": "SSRI",
    "option_b": "Methylphenedate",
    "option_c": "Serum oxybate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Narcolepsy is a central hypersomnolence disorder characterized primarily by excessive daytime sleepiness (EDS). Although changes in eating habits are not a classic symptom, some patients may experience altered appetite or weight gain, possibly related to disrupted circadian rhythms and decreased activity. The etiology of narcolepsy is most commonly linked to the destruction of orexin-producing neurons in the lateral hypothalamus, leading to an impaired regulation of the sleep\u2013wake cycle. Genetic and environmental factors, including strong associations with certain HLA alleles, are well documented in its pathogenesis. Patients suffer from profound daytime sleepiness that may interfere with daily activities and productivity. The occasional observation of increased eating or weight gain is thought to be secondary to metabolic changes and reduced physical activity associated with the disorder. Evaluation involves overnight polysomnography followed by a Multiple Sleep Latency Test (MSLT), which helps differentiate narcolepsy from conditions such as idiopathic hypersomnia and obstructive sleep apnea. A careful clinical history is essential in making the diagnosis. First-line management of EDS in narcolepsy typically involves modafinil or armodafinil. When these agents are not available or contraindicated, stimulants such as methylphenidate (option B) are acceptable alternatives. In pregnant patients, stimulant use is approached conservatively due to potential fetal risks (commonly classified as Category C), and non-pharmacologic interventions are encouraged. Lactating mothers should be counseled regarding the potential exposure through breast milk and monitored appropriately. Option A (SSRI) is primarily used for managing cataplexy by suppressing REM sleep phenomena rather than alleviating EDS. Option B (Methylphenidate) is a proven stimulant that effectively reduces EDS, making it the correct answer in this scenario. Option C (Serum oxybate) is more indicated for treating cataplexy and improving sleep consolidation rather than for primary management of daytime sleepiness. 1. The hallmark of narcolepsy is excessive daytime sleepiness due to orexin deficiency. 2. Although modafinil is generally the preferred agent, methylphenidate is an acceptable alternative when necessary. 3. Special considerations for pregnancy and lactation are critical when selecting pharmacotherapy. Recent studies and updated guidelines continue to underscore modafinil as the first-line treatment for narcolepsy-related EDS, with methylphenidate serving as a viable alternative. Ongoing research emphasizes a comprehensive treatment approach, including behavioral interventions and careful medication selection in vulnerable populations such as pregnant or breastfeeding women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "child with insomnia and low gonadotropin MRI showed agenesis of olfactory bulb:",
    "option_a": "HNPH",
    "option_b": "Kal-1",
    "option_c": "MEPRC",
    "option_d": "TSC1",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Kallmann syndrome is a developmental disorder characterized by the combination of hypogonadotropic hypogonadism and anosmia (or hyposmia) due to agenesis or hypoplasia of the olfactory bulbs. The disorder results from impaired migration of gonadotropin\u2010releasing hormone (GnRH)\u2013secreting neurons during embryogenesis. Mutations in the KAL-1 gene (which encodes the protein anosmin-1) disrupt the migration of GnRH neurons as well as the development of olfactory bulbs. This leads to low levels of gonadotropins, which in turn result in delayed or absent puberty. The X-linked inheritance is typical, though other genetic mutations may participate in some cases. Children with Kallmann syndrome often present with signs of hypogonadism such as delayed puberty. The absence or severe reduction of the sense of smell is a key clinical finding, which correlates with the radiologic finding of olfactory bulb agenesis. While insomnia is not a classic symptom, sleep disturbances can occasionally be associated with endocrine disorders. Diagnosis is based on clinical findings (delayed puberty, hypogonadism, and anosmia), supported by imaging studies (MRI showing olfactory bulb agenesis). Differential diagnoses include normosmic idiopathic hypogonadotropic hypogonadism. Genetic testing to identify mutations, especially in the KAL-1 gene, further confirms the diagnosis. Management involves hormone replacement therapy to induce and maintain secondary sexual characteristics and fertility. Pulsatile GnRH therapy may be considered to stimulate gonadotropin production. In pediatric patients, treatment is initiated in due course to induce puberty. Although not directly related to pregnancy or lactation, when patients reach reproductive age, fertility treatments and genetic counseling become important. Clinicians should tailor management in females considering potential estrogen therapy risks in pregnancy and lactation. Option A (HNPH) pertains to normal pressure hydrocephalus, which is unrelated. Option C (MEPRC) and Option D (TSC1) refer to unrelated conditions (MEPC is not a recognized gene in this context and TSC1 is associated with tuberous sclerosis), leaving Option B (Kal-1) as the sole appropriate choice linking the clinical and imaging findings to Kallmann syndrome. 1) The combination of hypogonadotropic hypogonadism and anosmia is pathognomonic for Kallmann syndrome. 2) MRI demonstrating agenesis or hypoplasia of the olfactory bulbs is a crucial diagnostic clue. 3) Early diagnosis allows timely hormone replacement, which is key to normal pubertal development. Recent studies continue to expand the genetic spectrum beyond KAL-1, with mutations in genes such as FGFR1, FGF8, and PROKR2 being implicated in Kallmann syndrome. Current guidelines emphasize multidisciplinary management including endocrinology, neurology, and genetics, and highlight the importance of early intervention for optimal outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II",
    "image_url": "page_1.png"
  },
  {
    "question": "child with insomnia and low gonadotropin MRI showed agenesis of olfactory bulb:",
    "option_a": "HNPH",
    "option_b": "Kal-1",
    "option_c": "MEPRC2",
    "option_d": "TSC1",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "This question describes a scenario consistent with Kallmann syndrome, which is characterized by hypogonadotropic hypogonadism due to impaired GnRH neuron migration and an associated deficit in olfaction, as evidenced by the agenesis of the olfactory bulb on MRI. The underlying mechanism involves a genetic mutation in the KAL-1 gene. This mutation disrupts the normal migration of GnRH-secreting neurons and the proper development of the olfactory bulbs, resulting in both reproductive and olfactory dysfunction. Patients typically present with signs of delayed puberty or hypogonadism accompanied by an impaired sense of smell. Although insomnia is not a classical feature of Kallmann syndrome, sleep disturbances can occur as part of a broader neurodevelopmental impact in some patients. The diagnosis rests on clinical findings\u2014low gonadotropin levels and anosmia\u2014and is confirmed by neuroimaging (MRI) showing the absence or hypoplasia of the olfactory bulbs. Differential diagnoses include other causes of hypogonadotropic hypogonadism without olfactory deficits, which helps delineate Kallmann syndrome from normosmic IHH. Management primarily involves hormone replacement therapy to induce secondary sexual characteristics and enable normal pubertal development. Pulsatile GnRH or gonadotropin therapy can also be considered for inducing fertility. In reproductive-age patients, careful evaluation and monitoring are needed, particularly in the context of pregnancy or lactation, requiring modified dosing and risk-benefit analysis. Option A (HNPH) is unrelated, as it stands for normal pressure hydrocephalus. Option C (MEPRC2) and Option D (TSC1) refer to irrelevant genetic conditions. Only Option B (Kal-1) correctly links the clinical presentation to Kallmann syndrome. 1) The dual presentation of hypogonadism and anosmia is highly suggestive of Kallmann syndrome. 2) MRI findings showing absence of the olfactory bulbs support the diagnosis. 3) Early endocrine evaluation is essential for timely initiation of therapy. Ongoing research has expanded the genetic understanding of Kallmann syndrome. Updated clinical practice guidelines recommend genetic counseling and a multidisciplinary approach to management, ensuring that endocrine, reproductive, and psychosocial needs are addressed.",
    "exam_year": "2021",
    "exam_type": "Part II",
    "image_url": "page_7.png"
  },
  {
    "question": "Young female with excessive daytime sleepiness, hyperphagia, and night time sleep issue (I forget) whats tx, no mention of cataplexy or other features of narcolepsy ..etc even no clear feature of kleine levin syndrome",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Sleep Neurology",
    "explanation": "The question describes a young female with excessive daytime sleepiness (EDS), hyperphagia, and nighttime sleep disturbances. However, the absence of key diagnostic features such as cataplexy (seen in narcolepsy) or the episodic, recurrent hypersomnia and behavioral changes typical of Kleine-Levin Syndrome (KLS) creates ambiguity in establishing a definitive diagnosis. In narcolepsy, the pathophysiology is linked to orexin (hypocretin) deficiency leading to uncontrollable sleep attacks, usually accompanied by cataplexy. In contrast, Kleine-Levin Syndrome is a rare disorder marked by intermittent episodes of hypersomnia, hyperphagia, and mood or behavioral disturbances. Without the complete constellation of symptoms, the underlying mechanism cannot be confidently assigned to either disorder. The patient\u2019s presentation of EDS and hyperphagia alone is insufficient for a definitive diagnosis of either narcolepsy or KLS. This uncertainty means that empirical treatment, such as using modafinil (commonly used in narcolepsy), may not be appropriate until further evaluation, including a detailed sleep history, polysomnography, and multiple sleep latency testing, is performed. A thorough workup for sleep disorders is recommended. Differential diagnoses may include idiopathic hypersomnia, narcolepsy (with or without cataplexy), and Kleine-Levin Syndrome. Polysomnography and a multiple sleep latency test (MSLT) are key studies utilized to distinguish between these conditions. Definitive treatment should only be initiated after a clear diagnosis is established. For confirmed narcolepsy, first-line therapy is usually modafinil, with alternatives such as sodium oxybate used based on the severity and presence of cataplexy. Conversely, in Kleine-Levin Syndrome, supportive and symptomatic management is preferred. In pregnant or lactating women, careful consideration of drug safety is crucial\u2014for instance, modafinil is generally classified as Category C, warranting caution. Given the diagnostic uncertainty in this case, initiating a specific treatment like modafinil is premature. While modafinil is effective for narcolepsy with EDS, its use is inappropriate here because the clinical features are not definitive for narcolepsy or any specific hypersomnia syndrome. Other treatments, such as sodium oxybate or psychostimulants, would similarly be contraindicated without a clear diagnosis. Hence, the best answer is 'None', indicating that no specific treatment decision can be made based solely on the provided information. 1) In sleep medicine, always secure the complete diagnostic criteria before initiating a targeted therapy. 2) Excessive daytime sleepiness has a broad differential; detailed sleep studies are essential. 3) Empiric treatment without a confirmed diagnosis may lead to inappropriate management, especially in women of childbearing potential. Recent guidelines emphasize an evidence-based, stepwise approach in diagnosing sleep disorders using polysomnography and MSLT. The importance of correlating clinical findings with objective test results is highlighted to avoid premature therapeutic interventions, particularly given the safety concerns of agents like modafinil in pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "patient with attached CT showed molar tooth, Dx:",
    "option_a": "Joubert syndrome.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "The 'molar tooth sign' is a radiologic finding that is highly characteristic of Joubert syndrome, a rare developmental disorder that affects the cerebellum and brainstem. This sign results from the abnormal configuration of these structures on axial brain imaging. Joubert syndrome arises from genetic mutations that impair the development of the midbrain-hindbrain region. The molar tooth sign reflects cerebellar vermis hypoplasia and malformation of the superior cerebellar peduncles. This malformation is part of a broader spectrum of ciliopathies where multiple organ systems may be affected. Clinically, Joubert syndrome often presents with hypotonia, ataxia, developmental delays, abnormal ocular movements, and episodic hyperpnea or apnea. The molar tooth sign on neuroimaging is a crucial finding that, alongside clinical features, confirms the diagnosis. Diagnosis is achieved through a combination of clinical evaluation and neuroimaging studies, primarily MRI. The differential diagnosis includes other cerebellar malformations such as Dandy-Walker malformation and cerebellar hypoplasia, but the molar tooth sign is unique to Joubert syndrome. Genetic testing can provide a definitive diagnosis and inform family counseling. Management of Joubert syndrome is supportive and multidisciplinary. It includes developmental therapies (physical, occupational, and speech therapies), regular monitoring for associated complications (such as renal and retinal issues), and genetic counseling. In pregnant patients or those considering pregnancy, preconception counseling is valuable for assessing recurrence risk and planning management. Option A (Joubert syndrome) is correct as the molar tooth sign is pathognomonic for this condition. The absence of any other provided options further reinforces that the listed diagnosis is appropriately matched with the radiologic finding. 1) The molar tooth sign is almost pathognomonic for Joubert syndrome. 2) Joubert syndrome is part of a group of disorders known as ciliopathies that can affect multiple organ systems. 3) Early multidisciplinary intervention improves developmental outcomes in affected children. Recent research focuses on the genetic heterogeneity of Joubert syndrome, with over 30 genes implicated. Current guidelines stress the need for comprehensive evaluation for multi-system involvement in affected patients and recommend regular follow\u2010up to manage the progressive aspects of the syndrome.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient sleeping with his movement the patient has aggressive movement in the legs while sleeping, he used to walk around at night, Dx:",
    "option_a": "parasomnia.",
    "option_b": "restless leg syndrome.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Parasomnias are a group of sleep disorders characterized by abnormal behaviors, movements, emotions, perceptions, or dreams that occur while falling asleep, during sleep, or upon waking. Sleepwalking (somnambulism), which involves walking or performing other complex behaviors while in a sleep state, is a classic example of a parasomnia. Parasomnias, including sleepwalking, are thought to result from incomplete transitions between sleep stages, particularly transitions between slow-wave (NREM) sleep and wakefulness. This state dissociation leads to a mix of sleep and wake characteristics, allowing complex motor activity without full awareness. Genetic predisposition, sleep deprivation, stress, and other factors may precipitate these episodes. Recent evidence emphasizes the role of neural circuits responsible for motor control and sleep regulation in the pathogenesis. Patients with parasomnias, such as sleepwalking, typically exhibit behaviors like getting out of bed, ambulating, or engaging in other activities during sleep with little or no recall of the event. In this case, the patient\u2019s aggressive leg movements and walking around at night align with the phenomenon of parasomnia rather than the sensory discomfort seen in restless legs syndrome. The diagnosis is largely clinical, based on a thorough sleep history and description of behaviors during sleep. Differential diagnoses include other sleep disorders such as restless legs syndrome (characterized by an urge to move the legs with unpleasant sensations during periods of rest) and REM sleep behavior disorder (RBD), where patients enact their dreams. Diagnostic tools like polysomnography (PSG) can help differentiate these conditions by revealing specific features such as the presence or absence of REM atonia. Management of parasomnias begins with safety measures: securing the environment (e.g., locking doors/windows, removing obstacles) to prevent injury. Behavioral modifications, such as maintaining regular sleep schedules, reducing stress, and avoiding sleep deprivation, are first-line. In cases where episodes are frequent or injurious, pharmacologic therapy (e.g., low-dose benzodiazepines like clonazepam) may be considered. For pregnant or lactating women, non-pharmacologic approaches and behavioral strategies are preferred given the potential risks associated with sedative medications. Consultation with a sleep specialist may be indicated if symptoms persist. Option A: Parasomnia is correct because the patient exhibits behaviors characteristic of sleepwalking \u2013 a type of parasomnia \u2013 such as performing complex motor tasks (walking and aggressive leg movements) during sleep without awareness. Option B: Restless leg syndrome is incorrect because RLS is primarily characterized by an unpleasant sensory experience leading to an urge to move the legs, predominantly during periods of inactivity or rest, and does not typically involve complex behaviors like sleepwalking. 1. Sleepwalking is most commonly seen in the context of NREM sleep and is often associated with factors such as sleep deprivation, stress, and certain medications. 2. Safety measures are critical in the management of parasomnias to prevent accidental injury. 3. Differentiating parasomnias from conditions like RLS is mainly based on the nature and timing of the symptoms. Recent guidelines and studies continue to support a conservative management strategy for parasomnias, emphasizing environmental safety and behavioral modifications as first-line interventions. Imaging and polysomnography are reserved for ambiguous cases. There is ongoing research into the neural mechanisms governing sleep state transitions, which may lead to improved pharmacologic treatments in the future. In pregnant or breastfeeding patients, current research favors non-pharmacologic management to mitigate potential risks associated with sedative agents.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with episode of upraising gastric sensation followed by laryngeal constriction, localization?",
    "option_a": "Insular",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests the recognition of visceral auras in focal epilepsy. Visceral symptoms such as an \u201cupraising gastric sensation\u201d combined with laryngeal constriction indicate activation of brain regions that process internal body sensations. The insular cortex is well known for its role in interoceptive awareness, autonomic regulation, and gustatory processing. Seizures originating in the insular cortex can produce abnormal visceral and somatosensory perceptions. Electrical discharges in the insula may trigger abnormal signals that are perceived as gastrointestinal discomfort and throat constriction. Recent intracranial EEG studies have confirmed that stimulation of the insular region can evoke these unusual visceral sensations. Patients with insular seizures may report a variety of visceral symptoms such as a rising epigastric sensation, laryngeal constriction, and sometimes even gustatory or thermal sensations. Recognizing these auras is important because they may precede more overt motor or behavioral seizure manifestations. Diagnosis relies on detailed clinical history and correlating semiology with neuroimaging and electrophysiological studies. Differential diagnoses include temporal lobe seizures (which can also produce epigastric auras) and autonomic dysfunction disorders. Advanced imaging (MRI, PET) and, when indicated, intracranial EEG can assist in differentiating an insular focus. Management of focal seizures typically begins with first\u2010line antiepileptic drugs such as levetiracetam, lamotrigine, or carbamazepine. For patients who are pregnant or lactating, lamotrigine is generally preferred because of its lower teratogenic potential. In refractory cases, further investigation with intracranial monitoring and possibly surgical resection may be considered. Option A (Insular) is selected because the insular cortex is specifically implicated in processing visceral sensations, including those felt in the stomach and larynx. The other options are omitted, and none better explain the combination of an epigastric rising sensation with laryngeal constriction. 1. Visceral auras (e.g., epigastric rising sensations) are common in seizures involving the insular cortex. 2. Insular involvement may manifest with unusual autonomic or gustatory symptoms not typical of other focal epilepsies. Recent neurophysiological and imaging studies have reinforced the role of the insular cortex in generating complex visceral auras. There is an increasing recognition in the literature of the insula\u2019s involvement in autonomic and sensory processing during seizures.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with first time seizure physical examination and EEG normal, regarding his risk of seizure recurrence?",
    "option_a": "He has 25% of seizure recurrence in 2 years",
    "option_b": "He has the highest risk of recurrence in the following 4 years",
    "option_c": "EEG findings has nothing to do with his risk of seizure recurrence",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests the recognition of visceral auras in focal epilepsy. Visceral symptoms such as an \u201cupraising gastric sensation\u201d combined with laryngeal constriction indicate activation of brain regions that process internal body sensations. The insular cortex is well known for its role in interoceptive awareness, autonomic regulation, and gustatory processing. Seizures originating in the insular cortex can produce abnormal visceral and somatosensory perceptions. Electrical discharges in the insula may trigger abnormal signals that are perceived as gastrointestinal discomfort and throat constriction. Recent intracranial EEG studies have confirmed that stimulation of the insular region can evoke these unusual visceral sensations. Patients with insular seizures may report a variety of visceral symptoms such as a rising epigastric sensation, laryngeal constriction, and sometimes even gustatory or thermal sensations. Recognizing these auras is important because they may precede more overt motor or behavioral seizure manifestations. Diagnosis relies on detailed clinical history and correlating semiology with neuroimaging and electrophysiological studies. Differential diagnoses include temporal lobe seizures (which can also produce epigastric auras) and autonomic dysfunction disorders. Advanced imaging (MRI, PET) and, when indicated, intracranial EEG can assist in differentiating an insular focus. Management of focal seizures typically begins with first\u2010line antiepileptic drugs such as levetiracetam, lamotrigine, or carbamazepine. For patients who are pregnant or lactating, lamotrigine is generally preferred because of its lower teratogenic potential. In refractory cases, further investigation with intracranial monitoring and possibly surgical resection may be considered. Option A (Insular) is selected because the insular cortex is specifically implicated in processing visceral sensations, including those felt in the stomach and larynx. The other options are omitted, and none better explain the combination of an epigastric rising sensation with laryngeal constriction. 1. Visceral auras (e.g., epigastric rising sensations) are common in seizures involving the insular cortex. 2. Insular involvement may manifest with unusual autonomic or gustatory symptoms not typical of other focal epilepsies. Recent neurophysiological and imaging studies have reinforced the role of the insular cortex in generating complex visceral auras. There is an increasing recognition in the literature of the insula\u2019s involvement in autonomic and sensory processing during seizures.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "In focal seizure where is the localization of seizure of semiology of absence:",
    "option_a": "Mesial temporal lobe",
    "option_b": "Occipital lobe",
    "option_c": "Frontal lobe",
    "option_d": "Parietal lobe",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests the recognition of visceral auras in focal epilepsy. Visceral symptoms such as an \u201cupraising gastric sensation\u201d combined with laryngeal constriction indicate activation of brain regions that process internal body sensations. The insular cortex is well known for its role in interoceptive awareness, autonomic regulation, and gustatory processing. Seizures originating in the insular cortex can produce abnormal visceral and somatosensory perceptions. Electrical discharges in the insula may trigger abnormal signals that are perceived as gastrointestinal discomfort and throat constriction. Recent intracranial EEG studies have confirmed that stimulation of the insular region can evoke these unusual visceral sensations. Patients with insular seizures may report a variety of visceral symptoms such as a rising epigastric sensation, laryngeal constriction, and sometimes even gustatory or thermal sensations. Recognizing these auras is important because they may precede more overt motor or behavioral seizure manifestations. Diagnosis relies on detailed clinical history and correlating semiology with neuroimaging and electrophysiological studies. Differential diagnoses include temporal lobe seizures (which can also produce epigastric auras) and autonomic dysfunction disorders. Advanced imaging (MRI, PET) and, when indicated, intracranial EEG can assist in differentiating an insular focus. Management of focal seizures typically begins with first\u2010line antiepileptic drugs such as levetiracetam, lamotrigine, or carbamazepine. For patients who are pregnant or lactating, lamotrigine is generally preferred because of its lower teratogenic potential. In refractory cases, further investigation with intracranial monitoring and possibly surgical resection may be considered. Option A (Insular) is selected because the insular cortex is specifically implicated in processing visceral sensations, including those felt in the stomach and larynx. The other options are omitted, and none better explain the combination of an epigastric rising sensation with laryngeal constriction. 1. Visceral auras (e.g., epigastric rising sensations) are common in seizures involving the insular cortex. 2. Insular involvement may manifest with unusual autonomic or gustatory symptoms not typical of other focal epilepsies. Recent neurophysiological and imaging studies have reinforced the role of the insular cortex in generating complex visceral auras. There is an increasing recognition in the literature of the insula\u2019s involvement in autonomic and sensory processing during seizures.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "53-year-old male who presented with first time GTC seizure physical examination and EEG were normal and he has no family history of epilepsy, what is his risk of seizure recurrence?",
    "option_a": "10%",
    "option_b": "30%",
    "option_c": "50%",
    "option_d": "70 %",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests the recognition of visceral auras in focal epilepsy. Visceral symptoms such as an \u201cupraising gastric sensation\u201d combined with laryngeal constriction indicate activation of brain regions that process internal body sensations. The insular cortex is well known for its role in interoceptive awareness, autonomic regulation, and gustatory processing. Seizures originating in the insular cortex can produce abnormal visceral and somatosensory perceptions. Electrical discharges in the insula may trigger abnormal signals that are perceived as gastrointestinal discomfort and throat constriction. Recent intracranial EEG studies have confirmed that stimulation of the insular region can evoke these unusual visceral sensations. Patients with insular seizures may report a variety of visceral symptoms such as a rising epigastric sensation, laryngeal constriction, and sometimes even gustatory or thermal sensations. Recognizing these auras is important because they may precede more overt motor or behavioral seizure manifestations. Diagnosis relies on detailed clinical history and correlating semiology with neuroimaging and electrophysiological studies. Differential diagnoses include temporal lobe seizures (which can also produce epigastric auras) and autonomic dysfunction disorders. Advanced imaging (MRI, PET) and, when indicated, intracranial EEG can assist in differentiating an insular focus. Management of focal seizures typically begins with first\u2010line antiepileptic drugs such as levetiracetam, lamotrigine, or carbamazepine. For patients who are pregnant or lactating, lamotrigine is generally preferred because of its lower teratogenic potential. In refractory cases, further investigation with intracranial monitoring and possibly surgical resection may be considered. Option A (Insular) is selected because the insular cortex is specifically implicated in processing visceral sensations, including those felt in the stomach and larynx. The other options are omitted, and none better explain the combination of an epigastric rising sensation with laryngeal constriction. 1. Visceral auras (e.g., epigastric rising sensations) are common in seizures involving the insular cortex. 2. Insular involvement may manifest with unusual autonomic or gustatory symptoms not typical of other focal epilepsies. Recent neurophysiological and imaging studies have reinforced the role of the insular cortex in generating complex visceral auras. There is an increasing recognition in the literature of the insula\u2019s involvement in autonomic and sensory processing during seizures.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Which AEDs exacerbate myoclonus?",
    "option_a": "Phenobarbital",
    "option_b": "Topiramate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Myoclonus, often seen in generalized epilepsies such as Juvenile Myoclonic Epilepsy (JME), is very sensitive to the choice of antiepileptic drugs (AEDs). Certain AEDs\u2014especially those that work primarily by blocking sodium channels\u2014can paradoxically worsen myoclonic jerks. In clinical practice, it is well established that drugs like carbamazepine (typically represented by option C in complete question sets) should be avoided in patients with myoclonic components. Sodium channel blockers such as carbamazepine can alter neuronal excitability by inhibiting the inactivation phase of voltage-gated sodium channels. In patients with a predisposition to myoclonus, this alteration can shift the balance between excitatory and inhibitory influences, leading to paradoxical seizure exacerbation. Recent evidence confirms that interference with normal synaptic modulation in generalized epileptic networks can provoke or worsen myoclonic jerks. Patients with JME usually report early-morning myoclonic jerks along with generalized tonic-clonic seizures. When prescribed sodium channel blockers (e.g., carbamazepine), these patients may experience a worsening in the frequency and severity of myoclonic episodes. Recognizing this association is crucial to prevent worsening of seizure control. Diagnosis is achieved through a combination of patient history, seizure semiology, and EEG findings (such as polyspike-and-slow wave complexes). Differential diagnoses include other myoclonic disorders (e.g., metabolic myoclonus) but the context of generalized epilepsy and specific EEG findings help to clarify the diagnosis. First-line management for JME involves medications such as valproate, levetiracetam, or, in selected cases, lamotrigine (with cautious titration because of its sometimes paradoxical effects). Drugs like carbamazepine should be avoided because they can exacerbate myoclonic activity. In women of childbearing potential and during pregnancy and lactation, levetiracetam and lamotrigine are often preferred due to a more favorable teratogenic profile compared to valproate. Option A (Phenobarbital) is not typically associated with exacerbating myoclonus and has a less favorable side effect profile. Option B (Topiramate) does not have a strong association with worsening myoclonic jerks and is sometimes used in various generalized seizure types. Option C, assumed to represent carbamazepine, is well known for aggravating myoclonic seizures, making it the correct choice. Option D is not provided. 1. Avoid sodium channel blockers such as carbamazepine in patients with myoclonic seizures, particularly in JME. 2. Always tailor AED selection to the seizure type and underlying syndrome. 3. Recognize that misclassification of epilepsy type can lead to inappropriate AED use and seizure worsening. Recent research and clinical guidelines continue to emphasize that in generalized epilepsies with a myoclonic component, the use of sodium channel blockers (e.g., carbamazepine) can worsen seizure control. Updated treatment algorithms recommend valproate, levetiracetam, or cautious use of lamotrigine in appropriate patients, with special consideration given to women of childbearing age.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "EEG changes associated with Hyperventilation?",
    "option_a": "generalized delta/ theta",
    "option_b": "prominent anterior slowing",
    "option_c": "No changes",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Myoclonus, often seen in generalized epilepsies such as Juvenile Myoclonic Epilepsy (JME), is very sensitive to the choice of antiepileptic drugs (AEDs). Certain AEDs\u2014especially those that work primarily by blocking sodium channels\u2014can paradoxically worsen myoclonic jerks. In clinical practice, it is well established that drugs like carbamazepine (typically represented by option C in complete question sets) should be avoided in patients with myoclonic components. Sodium channel blockers such as carbamazepine can alter neuronal excitability by inhibiting the inactivation phase of voltage-gated sodium channels. In patients with a predisposition to myoclonus, this alteration can shift the balance between excitatory and inhibitory influences, leading to paradoxical seizure exacerbation. Recent evidence confirms that interference with normal synaptic modulation in generalized epileptic networks can provoke or worsen myoclonic jerks. Patients with JME usually report early-morning myoclonic jerks along with generalized tonic-clonic seizures. When prescribed sodium channel blockers (e.g., carbamazepine), these patients may experience a worsening in the frequency and severity of myoclonic episodes. Recognizing this association is crucial to prevent worsening of seizure control. Diagnosis is achieved through a combination of patient history, seizure semiology, and EEG findings (such as polyspike-and-slow wave complexes). Differential diagnoses include other myoclonic disorders (e.g., metabolic myoclonus) but the context of generalized epilepsy and specific EEG findings help to clarify the diagnosis. First-line management for JME involves medications such as valproate, levetiracetam, or, in selected cases, lamotrigine (with cautious titration because of its sometimes paradoxical effects). Drugs like carbamazepine should be avoided because they can exacerbate myoclonic activity. In women of childbearing potential and during pregnancy and lactation, levetiracetam and lamotrigine are often preferred due to a more favorable teratogenic profile compared to valproate. Option A (Phenobarbital) is not typically associated with exacerbating myoclonus and has a less favorable side effect profile. Option B (Topiramate) does not have a strong association with worsening myoclonic jerks and is sometimes used in various generalized seizure types. Option C, assumed to represent carbamazepine, is well known for aggravating myoclonic seizures, making it the correct choice. Option D is not provided. 1. Avoid sodium channel blockers such as carbamazepine in patients with myoclonic seizures, particularly in JME. 2. Always tailor AED selection to the seizure type and underlying syndrome. 3. Recognize that misclassification of epilepsy type can lead to inappropriate AED use and seizure worsening. Recent research and clinical guidelines continue to emphasize that in generalized epilepsies with a myoclonic component, the use of sodium channel blockers (e.g., carbamazepine) can worsen seizure control. Updated treatment algorithms recommend valproate, levetiracetam, or cautious use of lamotrigine in appropriate patients, with special consideration given to women of childbearing age.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Lady with DM on multiple anti-DM mediations, HTN, Osteoporosis, had complex partial epilepsy what medications will you give:",
    "option_a": "Carbamazepine",
    "option_b": "Valproic acid",
    "option_c": "lamotrigine",
    "option_d": "Phenytoin",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Myoclonus, often seen in generalized epilepsies such as Juvenile Myoclonic Epilepsy (JME), is very sensitive to the choice of antiepileptic drugs (AEDs). Certain AEDs\u2014especially those that work primarily by blocking sodium channels\u2014can paradoxically worsen myoclonic jerks. In clinical practice, it is well established that drugs like carbamazepine (typically represented by option C in complete question sets) should be avoided in patients with myoclonic components. Sodium channel blockers such as carbamazepine can alter neuronal excitability by inhibiting the inactivation phase of voltage-gated sodium channels. In patients with a predisposition to myoclonus, this alteration can shift the balance between excitatory and inhibitory influences, leading to paradoxical seizure exacerbation. Recent evidence confirms that interference with normal synaptic modulation in generalized epileptic networks can provoke or worsen myoclonic jerks. Patients with JME usually report early-morning myoclonic jerks along with generalized tonic-clonic seizures. When prescribed sodium channel blockers (e.g., carbamazepine), these patients may experience a worsening in the frequency and severity of myoclonic episodes. Recognizing this association is crucial to prevent worsening of seizure control. Diagnosis is achieved through a combination of patient history, seizure semiology, and EEG findings (such as polyspike-and-slow wave complexes). Differential diagnoses include other myoclonic disorders (e.g., metabolic myoclonus) but the context of generalized epilepsy and specific EEG findings help to clarify the diagnosis. First-line management for JME involves medications such as valproate, levetiracetam, or, in selected cases, lamotrigine (with cautious titration because of its sometimes paradoxical effects). Drugs like carbamazepine should be avoided because they can exacerbate myoclonic activity. In women of childbearing potential and during pregnancy and lactation, levetiracetam and lamotrigine are often preferred due to a more favorable teratogenic profile compared to valproate. Option A (Phenobarbital) is not typically associated with exacerbating myoclonus and has a less favorable side effect profile. Option B (Topiramate) does not have a strong association with worsening myoclonic jerks and is sometimes used in various generalized seizure types. Option C, assumed to represent carbamazepine, is well known for aggravating myoclonic seizures, making it the correct choice. Option D is not provided. 1. Avoid sodium channel blockers such as carbamazepine in patients with myoclonic seizures, particularly in JME. 2. Always tailor AED selection to the seizure type and underlying syndrome. 3. Recognize that misclassification of epilepsy type can lead to inappropriate AED use and seizure worsening. Recent research and clinical guidelines continue to emphasize that in generalized epilepsies with a myoclonic component, the use of sodium channel blockers (e.g., carbamazepine) can worsen seizure control. Updated treatment algorithms recommend valproate, levetiracetam, or cautious use of lamotrigine in appropriate patients, with special consideration given to women of childbearing age.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Which of these is a characteristic of LGS:",
    "option_a": "Resistant to antiepileptic medications",
    "option_b": "Peak onset 5-10 years",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Myoclonus, often seen in generalized epilepsies such as Juvenile Myoclonic Epilepsy (JME), is very sensitive to the choice of antiepileptic drugs (AEDs). Certain AEDs\u2014especially those that work primarily by blocking sodium channels\u2014can paradoxically worsen myoclonic jerks. In clinical practice, it is well established that drugs like carbamazepine (typically represented by option C in complete question sets) should be avoided in patients with myoclonic components. Sodium channel blockers such as carbamazepine can alter neuronal excitability by inhibiting the inactivation phase of voltage-gated sodium channels. In patients with a predisposition to myoclonus, this alteration can shift the balance between excitatory and inhibitory influences, leading to paradoxical seizure exacerbation. Recent evidence confirms that interference with normal synaptic modulation in generalized epileptic networks can provoke or worsen myoclonic jerks. Patients with JME usually report early-morning myoclonic jerks along with generalized tonic-clonic seizures. When prescribed sodium channel blockers (e.g., carbamazepine), these patients may experience a worsening in the frequency and severity of myoclonic episodes. Recognizing this association is crucial to prevent worsening of seizure control. Diagnosis is achieved through a combination of patient history, seizure semiology, and EEG findings (such as polyspike-and-slow wave complexes). Differential diagnoses include other myoclonic disorders (e.g., metabolic myoclonus) but the context of generalized epilepsy and specific EEG findings help to clarify the diagnosis. First-line management for JME involves medications such as valproate, levetiracetam, or, in selected cases, lamotrigine (with cautious titration because of its sometimes paradoxical effects). Drugs like carbamazepine should be avoided because they can exacerbate myoclonic activity. In women of childbearing potential and during pregnancy and lactation, levetiracetam and lamotrigine are often preferred due to a more favorable teratogenic profile compared to valproate. Option A (Phenobarbital) is not typically associated with exacerbating myoclonus and has a less favorable side effect profile. Option B (Topiramate) does not have a strong association with worsening myoclonic jerks and is sometimes used in various generalized seizure types. Option C, assumed to represent carbamazepine, is well known for aggravating myoclonic seizures, making it the correct choice. Option D is not provided. 1. Avoid sodium channel blockers such as carbamazepine in patients with myoclonic seizures, particularly in JME. 2. Always tailor AED selection to the seizure type and underlying syndrome. 3. Recognize that misclassification of epilepsy type can lead to inappropriate AED use and seizure worsening. Recent research and clinical guidelines continue to emphasize that in generalized epilepsies with a myoclonic component, the use of sodium channel blockers (e.g., carbamazepine) can worsen seizure control. Updated treatment algorithms recommend valproate, levetiracetam, or cautious use of lamotrigine in appropriate patients, with special consideration given to women of childbearing age.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "What is the sign on Brain MRI of patient with intracranial hypotension:",
    "option_a": "leptomeningeal enhancement",
    "option_b": "Decrease venous sinuses size",
    "option_c": "Pituitary enlargement",
    "option_d": "Decrease anterior posterior diameter of brainstem",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Intracranial hypotension is a condition most frequently resulting from leakage of cerebrospinal fluid (CSF), which lowers intracranial pressure. This drop in CSF pressure leads to a series of compensatory imaging findings on brain MRI, including engorgement of venous structures and subtle morphologic changes. When CSF volume decreases, the brain sags due to loss of buoyant support and the intracranial compartment attempts to compensate by increasing blood volume. This venous engorgement can cause structures such as the pituitary gland to appear enlarged on imaging. Additionally, diffuse pachymeningeal (dural) enhancement occurs because of the dilated, engorged dura; note that true leptomeningeal enhancement is not typical of this condition. Patients typically present with orthostatic headaches that improve when lying down. The pituitary enlargement seen on MRI is a radiologic manifestation of venous engorgement rather than a primary pituitary disorder. Diagnosis relies on a combination of clinical history (notably orthostatic headache) and characteristic MRI findings. Differential diagnoses include meningitis (which shows leptomeningeal rather than pachymeningeal enhancement) and intracranial mass lesions. Gadolinium-enhanced MRI is the modality of choice to identify these features, including brain sagging, pachymeningeal enhancement, and pituitary enlargement. First-line management involves conservative measures such as bed rest, hydration, and caffeine. If symptoms do not improve, an epidural blood patch is typically recommended. In pregnant or lactating women, non-invasive management is preferred and imaging should be carefully justified with minimized radiation exposure and appropriate shielding when needed. Option A (leptomeningeal enhancement) is incorrect because the classic finding is pachymeningeal enhancement. Option B (decrease in venous sinuses size) is not a recognized feature. Option C (pituitary enlargement) is correct as it reflects compensatory venous engorgement. Option D (decrease in the anterior-posterior diameter of the brainstem) is not a typical finding in intracranial hypotension. \u2022 Intracranial hypotension commonly presents with orthostatic headache. \u2022 MRI typically shows pachymeningeal enhancement and brain sagging. \u2022 Pituitary enlargement is due to venous engorgement, not a primary pituitary pathology. Recent guidelines underscore the role of high-resolution MRI in identifying subtle signs such as pituitary enlargement in intracranial hypotension, emphasizing early conservative intervention and the use of epidural blood patches when indicated.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "page_9.png"
  },
  {
    "question": "Which condition Shows slow spike and wave?",
    "option_a": "Absence seizure",
    "option_b": "LGS",
    "option_c": "Generalized epilepsy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Electroencephalography (EEG) patterns are critical in the classification of epileptic syndromes. Slow spike-wave discharges are a notable EEG pattern that is most characteristically seen in certain severe childhood epilepsies. In conditions such as Lennox-Gastaut syndrome (LGS), there is widespread cortical dysfunction that disrupts normal neuronal firing. This disruption results in slow (typically 1\u20132.5 Hz) spike-wave discharges that represent disorganized electrical activity. Patients with LGS exhibit multiple seizure types, including tonic, atonic, and atypical absence seizures. The slow spike-wave pattern on EEG is a diagnostic clue and correlates with the severe and refractory nature of the seizure disorder. The EEG pattern helps differentiate LGS from other generalized epilepsies. For instance, typical absence seizures usually demonstrate faster, 3 Hz spike-wave discharges. Clinical history and age of onset are also important in differentiating LGS from other epileptic syndromes. Management of LGS is challenging. First-line therapies typically include valproate, lamotrigine, and topiramate. In refractory cases, options such as the ketogenic diet, clobazam, and rufinamide may be considered. For women of childbearing age, careful AED selection is necessary to balance seizure control with teratogenic risk; pregnancy planning and counseling are essential. Option A (Absence seizure) is incorrect because absence seizures classically exhibit a 3 Hz spike-wave pattern rather than slow spike-wave discharges. Option B (LGS) is correct, as the syndrome is best known for its slow spike-wave pattern. Option C (Generalized epilepsy) is too broad and nonspecific. Option D is missing and hence not applicable. \u2022 Slow spike-wave discharges (1\u20132.5 Hz) are a hallmark of LGS. \u2022 Differentiating LGS from typical absence seizures is crucial for accurate treatment planning. \u2022 LGS is an epileptic encephalopathy with multiple seizure types. Recent research emphasizes an individualized approach to LGS management, incorporating newer AEDs and non-pharmacological interventions while also considering the impact of treatment on quality of life, especially in women of childbearing age.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Female patient known to have seizure, complex partial seizure, with GTC 2 attack per week. EEG Temporal spikes and MRI showed mesial temporal sclerosis. She tried Dilantin (phenytoin) before but not improved. Then she started on carbamazepine & Keppra. came after 1 year follow up, she reported improved of complex partial seizure & no GTC. And the attack of seizure become once per month. What is the next appropriate management?",
    "option_a": "Follow up after 6 months & adjust the AED",
    "option_b": "Send for pre-surgical evaluation",
    "option_c": "Add 3rd drug (Depakene)",
    "option_d": "Vagus nerve stimulation",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Temporal lobe epilepsy, particularly when associated with mesial temporal sclerosis (MTS), is one of the most common forms of drug-resistant epilepsy. The failure of adequate trials on at least two appropriate antiepileptic drugs (AEDs) is a benchmark for considering surgical intervention. Mesial temporal sclerosis involves scarring and neuronal loss in the hippocampus and surrounding mesial temporal structures. This focal pathology leads to abnormal electrical discharges that are often resistant to medical management. Patients often present with complex partial seizures that may secondarily generalize. The presence of temporal spikes on EEG and radiologic evidence of MTS on MRI supports the diagnosis. Despite partial improvement with AEDs, persistent seizures\u2014especially when they remain disabling\u2014warrant further evaluation. The evaluation of refractory epilepsy involves prolonged video-EEG monitoring, detailed neuroimaging (typically high-resolution MRI), and neuropsychological testing. Differential diagnoses include other focal epilepsies or multifocal epilepsies, but the presence of MTS and temporal spikes strongly point toward mesial temporal lobe epilepsy. The current guidelines advocate for early referral for epilepsy surgery evaluation in patients with drug-resistant temporal lobe epilepsy after failure of two appropriate AED regimens. Surgical resection has been demonstrated to provide seizure freedom or significant seizure reduction in a substantial percentage of patients. In pregnancy or lactation, while medication adjustments must consider fetal/neonatal risks, surgical evaluation is generally based on refractory status rather than pregnancy status; decisions should be tailored to the individual after multidisciplinary consultation. Option A (Continue follow-up with adjustment of AEDs) is less optimal for drug-resistant epilepsy. Option B (Send for pre-surgical evaluation) is correct because mesial temporal sclerosis with ongoing seizures despite medical therapy qualifies the patient for surgical workup. Option C (Add a third drug such as Depakene) is typically not recommended after failure of two adequate trials. Option D (Vagus nerve stimulation) is usually reserved for patients who are not candidates for resective surgery. \u2022 Mesial temporal sclerosis is the most common pathology in drug-resistant temporal lobe epilepsy. \u2022 Surgery (anterior temporal lobectomy) can be curative or substantially reduce seizure frequency in selected patients. \u2022 Failure of two adequate AED trials defines pharmacoresistance. Emerging studies continue to support the efficacy of surgical intervention in refractory temporal lobe epilepsy, with many centers advocating for early pre-surgical evaluation to optimize long-term outcomes. Recent guidelines also stress the importance of comprehensive evaluation to identify surgical candidates.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]